(NEW LINE)Warner-Lambert's Lopid

(NEW LINE)Warner-Lambert's Lopid: FDA Endocrinologic & Metabolic Drugs Advisory Committee will review Helsinki Heart Study results in support of a claim for prevention of coronary heart disease on Oct. 17. Meeting will be held at National Institute of Health's Jack Masur Auditorium, beginning at 9:00 a.m. Company announced Sept. 19 that it has received a patent extension for Lopid (gemfibrozil) to Jan. 4, 1993 from the U.S. Patent and Trademark Office under the recently passed trade bill. The patient restoration is contingent on FDA approval of the new claim.